This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (23) Citing Articles via Google Scholar Google Scholar Articles by Lee, S.-W. Articles by Park, S.-J. Search for Related Content PubMed Articles by Lee, S.-W. Articles by Park, S.-J. Related Collections Related Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes Mellitus

The DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients)

Seung-Whan Lee, MD, PhD^_*, Seong-Wook Park, MD, PhD, FACC^_*,_*, Young-Hak Kim, MD, PhD^_*, Sung-Cheol Yun, PhD^_*, Duk-Woo Park, MD, PhD^_*, Cheol Whan Lee, MD, PhD^_*, Myeong-Ki Hong, MD, PhD^_*, Hyun-Sook Kim, MD, PhD, Jae-Ki Ko, MD, PhD, Jae-Hyeong Park, MD, PhD, Jae-Hwan Lee, MD, Si Wan Choi, MD, In-Whan Seong, MD, PhD, Yoon Haeng Cho, MD, PhD, Nae-Hee Lee, MD, PhD, June Hong Kim, MD, PhD^||, Kook-Jin Chun, MD^|| and Seung-Jung Park, MD, PhD, FACC^_*

^_* Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Chonbuk National University Hospital, Jeonju, Korea
Chungnam National University Hospital, Daejeon, Korea
Soonchunhyang University Bucheon Hospital, Bucheon, Korea
^|| Busan National University Hospital, Busan, Korea.

Manuscript received August 6, 2007; revised manuscript received November 12, 2007, accepted November 13, 2007.

^_* Reprint requests and correspondence: Dr. Seong-Wook Park, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388–1 Poongnap–dong, Songpa-gu, Seoul, 138-736, Korea. (Email: swpark{at}amc.seoul.kr).

Objectives: We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM).

Background: Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients.

Methods: This randomized, multicenter, prospective study compared triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol, triple group, n = 200) and dual antiplatelet therapy (aspirin and clopidogrel, standard group, n = 200) for 6 months in patients with DM receiving DES. The primary end point was in-stent late loss at 6 months.

Results: The 2 groups had similar baseline clinical and angiographic characteristics. The in-stent (0.25 ± 0.53 mm vs. 0.38 ± 0.54 mm, p = 0.025) and in-segment (0.42 ± 0.50 mm vs. 0.53 ± 0.49 mm, p = 0.031) late loss were significantly lower in the triple versus standard group, as were 6-month in-segment restenosis (8.0% vs. 15.6%, p = 0.033) and 9-month target lesion revascularization (TLR) (2.5% vs. 7.0%, p = 0.034). At 9 months, major adverse cardiac events, including death, myocardial infarction, and TLR, tended to be lower in the triple than in the standard group (3.0% vs. 7.0%, p = 0.066). Multivariate analysis showed that sirolimus-eluting stents and the use of cilostazol were strong predictors of reduced restenosis or TLR.

Conclusions: Triple antiplatelet therapy after DES implantation decreased angiographic restenosis and extent of late loss, resulting in a reduced risk of 9-month TLR compared with dual antiplatelet therapy in diabetic patients.

Abbreviations and Acronyms   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   MACE = major adverse cardiac events   MI = myocardial infarction   PES = paclitaxel-eluting stent(s)   QCA = quantitative coronary angiography   SES = sirolimus-eluting stent(s)   TLR = target lesion revascularization   TVR = target vessel revascularization

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A31-A32. [Full Text] [PDF]

This article has been cited by other articles:

				K.-Y. Chen, S.-W. Rha, Y.-J. Li, K. L. Poddar, Z. Jin, Y. Minami, L. Wang, E. J. Kim, C. G. Park, H. S. Seo, et al. Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Circulation, June 30, 2009; 119(25): 3207 - 3214. [Abstract] [Full Text] [PDF]

				H. Ota, M. Eto, J. Ako, S. Ogawa, K. Iijima, M. Akishita, and Y. Ouchi Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2298 - 2305. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				D. J. Angiolillo Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions Diabetes Care, April 1, 2009; 32(4): 531 - 540. [Full Text] [PDF]

				Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1101 - 1109. [Abstract] [Full Text] [PDF]

				A. K. Chhatriwalla and D. L. Bhatt Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely Circ Cardiovasc Interv, December 1, 2008; 1(3): 217 - 225. [Full Text] [PDF]

				D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur. Heart J., September 2, 2008; 29(18): 2202 - 2211. [Abstract] [Full Text] [PDF]

				J. H. Chesebro Diabetic atherothrombosis: helpful adjunctive therapy Eur. Heart J., September 2, 2008; 29(18): 2191 - 2192. [Full Text] [PDF]

				S. N. Hayes and R. F. Redberg Dispelling the Myths: Calling for Sex-Specific Reporting of Trial Results Mayo Clin. Proc., May 1, 2008; 83(5): 523 - 525. [Full Text] [PDF]